Omega Therapeutics IPO Presentation Deck

In vitro Specificity Data in Oncology Program - HCC Targeting specific EpiZip within diseased IGD enables selective cellular modulation in cancer cells; lack of modulation in normal primary cells % Untreated 120 100- 80 60- 40 20- 0 OECS targets Epizip to downregulate MYC expression Negative control Ⓒ2021 Omega Therapeutics, Inc. Cancer cells MYC expression is dysregulated Cell Viability 0.5ug/mL 1ug/mL ➡2ug/mL OEC % Untreated 120- 100- 80- 60 40 20- 0 Lowered MYC protein primes cells to undergo apoptosis Negative control Normal cells MYC expression is properly regulated OEC 0.5ug/mL 1ug/mL 2ug/mL 19

View entire presentation